Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia

Mohammed Saif, M., S. F. Farid, S. A. Khaleel, N. A. Sabry, and M. H. El-Sayed, "Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia", Pediatric Hematology and Oncology, vol. 29, issue 7, pp. 627 - 632, 2012.


Ursodeoxycholic acid (UDCA) possesses a hepatoprotective effect in drug-induced hepatotoxicity. In a prospective randomized parallel study, 39 children with acute lymphoblastic leukemia (ALL) were randomized to receive UDCA with chemotherapy for 6 months, then discontinued UDCA and were followed up for 3 months, (UDCA group) (N = 19) or receive chemotherapy without UDCA and followed up for 9 months (control group) (N = 20). In this pilot study, UDCA treatment was associated with a trend toward decreased levels of hepatic transaminases when concomitantly administered with chemotherapy and, therefore, safer outcome in children with ALL. Future studies with a larger sample size are needed to confirm the efficacy and safety of UDCA in this setting. © 2012 Informa Healthcare USA, Inc.


Cited By :7Export Date: 19 July 2022

Related External Link